



17W


DOCKET NO.: D0617.70012US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Sato et al.  
Serial No.: 10/661,156  
Confirmation No.: 6772  
Filed: September 11, 2003  
For: KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN  
DIAGNOSIS AND THERAPY  
Examiner: Anand U. Desai  
Art Unit: 1653

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 25<sup>th</sup> day of July, 2006.

  
Emily E. Zinkauskas

MAIL STOP AMENDMENT

Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:


- Information Disclosure Statement
- PTO Form 1449 with cited references
- Copy of European Search Report (EP 03711418.8) dated April 21, 2006
- Copy of European Search Report (EP 03770325.3) dated April 21, 2006
- Copy of International Search Report and Written Opinion (PCT/US2005/032740) dated June 13, 2006
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

By:

  
Michael T. Siekman, Reg. No.: 36,276  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2206  
Telephone: (617) 646-8000

Docket No.: D0617.70012US00  
Date: July 25, 2006  
xNDDx

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the enclosed search report or other communication from a corresponding or other International or Foreign National Application.

<u>Serial No.</u>	<u>Mailing Date</u>	<u>Type(s) of Communication</u>	<u>Docket No.</u>
EP 03711418.8	April 21, 2006	Partial European Search Report	D0617.70011EP00
EP 03770325.3	April 21, 2006	Partial European Search Report	D0617.70012EP00
PCT/US2005/032740	June 13, 2006	International Search Report and Written Opinion	D0617.70014WO00

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,


By:



Michael T. Siekman, Reg. No. 36,276  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2206  
Telephone: (617) 646-8000

Docket No.: D0617.70012US00  
Date: July 25, 2006  
xNDDx

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		APPLICATION NO.: 10/661,156	ATTY. DOCKET NO.: D0617.70012US00
		FILING DATE: September 11, 2003	CONFIRMATION NO.: 6772
		APPLICANT: Sato et al.	
		GROUP ART UNIT: 1653	EXAMINER: Anand U. Desai
Sheet 1 of 4			



**U.S. PATENT DOCUMENTS**

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A45	5,547,656		Unger	08-20-1996
	A46	6,033,645		Unger et al.	03-07-2000
	A47	6,130,071		Alitalo et al.	10-10-2000
	A48	6,231,834	B1	Unger et al.	05-15-2001
	A49	6,245,318	B1	Klibanov et al.	06-12-2001
	A50	6,528,039	B2	Unger	03-04-2003
	A51	6,537,520	B1	Rajopadhye et al.	03-25-2003
	A52	6,548,048	B1	Cuthbertson et al.	05-14-2003
	A53	6,548,663	B1	Cheesman et al.	04-15-2003
	A54	6,610,269	B1	Klaveness et al.	08-26-2003
	A55	6,680,047	B2	Klaveness et al.	01-20-2004
	A56	6,730,658	B1	Alitalo et al.	05-04-2004
	A57	6,773,696	B2	Unger	08-10-2004
	A58	6,777,534	B1	Klagsbrun et al.	08-17-2004
	A59	6,818,220		Alitalo et al.	11-16-2004
	A60	6,841,367	B2	Kendall et al.	01-11-2005
	A61	6,841,382	B2	Kendall et al.	01-11-2005
	A62	6,875,741	B2	Pillutla et al.	04-05-2005
	A63	7,034,105	B2	Alitalo et al.	04-25-2006
	A64	2002-0010137	A1	Ashkenazi et al.	01-24-2002
	A65	2002-0037289	A1	Thorpe et al.	03-28-2002
	A66	2002-0102215	A1	Klaveness et al.	08-01-2002
	A67	2002-0164667	A1	Alitalo et al.	11-07-2002
	A68	2003-0027246	A1	Pedyczak et al.	02-06-2003
	A69	2003-0124120	A1	Harris	07-03-2003
	A70	2003-0149262	A1	Cheesman et al.	08-07-2003
	A71	2003-0157025	A1	Unger et al.	08-21-2003
	A72	2003-0166873	A1	Lee et al.	09-04-2003
	A73	2003-0180718	A1	Pillutla et al.	09-25-2003
	A74	2003-0236190	A1	Pillutla et al.	12-25-2003
	A75	2004-0009122	A1	Klaveness et al.	01-15-2004
	A76	2004-0023887	A1	Pillutla et al.	02-05-2004

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/661,156		ATTY. DOCKET NO.: D0617.70012US00			
				FILING DATE: September 11, 2003		CONFIRMATION NO.: 6772			
				APPLICANT: Sato et al.					
				GROUP ART UNIT: 1653		EXAMINER: Anand U. Desai			
Sheet	2	of	4						

	A77	2004-0141922	A1	Klaveness et al.	07-22-2004
	A78	2004-0147448	A1	Alitalo et al.	07-29-2004
	A79	2004-0147449	A1	Siemeister et al.	07-29-2004
	A80	2004-0147726	A1	Alitalo et al.	07-29-2004
	A81	2004-0213790	A1	Lee et al.	10-28-2004
	A82	2004-0223911	A1	Bednarski et al.	11-11-2004
	A83	2004-0224398	A1	Anand-Apte	11-11-2004
	A84	2004-0248781	A1	Kerbel	12-09-2004
	A85	2004-0266694	A1	Tchistiakova et al.	12-30-2004
	A86	2005-0002865	A1	Klaveness et al.	01-06-2005
	A87	2005-0037967	A1	Rosenblum	02-17-2005
	A88	2005-0181995	A1	Kawai et al.	08-18-2005
	A89	2006-0003926	A1	Rajopadhye et al.	01-05-2006
	A90	2006-0008930	A1	Toyoda et al.	01-12-2006
	A91	2006-0078501	A1	Goertz et al.	04-13-2006

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	B37	EP	0 580 726	B1	Unger	02-02-1994	
	B38	EP	0 627 940	B1	University of Texas	12-14-1994	
	B39	EP	0 711 127	B1	Unger	06-15-1996	
	B40	EP	0 804 932	A2	ImaRx Pharmaceutical Corp.	11-05-1997	
	B41	EP	1 064 376		Genentech, Inc.	01-03-2001	
	B42	EP	1 081 913	A2	Phillips Corporate Intellectual Property GmbH	03-07-2001	
	B43	EP	1 306 095	A2	University of Texas	05-02-2003	
	B44	EP	1 432 433		Novo Nordisk A/S	06-30-2004	
	B45	EP	1 519 193	A2	Ludwig Institute for Cancer Research	03-30-2005	
	B46	EP	1 574 518	A2	Nec Soft, Ltd.	09-14-2005	
	B47	EP	1 586 333	A2	Schering Aktiengesellschaft	10-19-2005	
	B48	WO	97/05250	A2	Helsinki University Licensing Ltd	02-13-1997	
	B49	WO	97/09427	A1	Genentech, Inc.	03-13-1997	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/661,156		ATTY. DOCKET NO.: D0617.70012US00			
				FILING DATE: September 11, 2003		CONFIRMATION NO.: 6772			
				APPLICANT: Sato et al.					
				GROUP ART UNIT: 1653		EXAMINER: Anand U. Desai			
Sheet	3	of	4						

	B50	WO	98/18495	A2	Nycomed Imaging AS	05-07-1998	
	B51	WO	98/18500	A2	Nycomed Imaging AS	05-07-1998	
	B52	WO	98/33917	A1	The Ludwig Institute for Cancer Research	08-06-1998	
	B53	WO	98/58053	A1	Kendall	12-23-1998	
	B54	WO	99/55383	A2	Nycomed Imaging AS	11-04-1999	
	B55	WO	00/63380	A1	Genentech, Inc.	10-26-2000	
	B56	WO	01/52875	A1	Ludwig Institute for Cancer Research	07-26-2001	
	B57	WO	01/57067	A1	Supratek Pharma Inc.	08-09-2001	
	B58	WO	02/16412	A2	Dyax Corp.	02-28-2002	
	B59	WO	02/72011	A2	Targesome, Inc.	09-19-2002	
	B60	WO	02/96367	A2	Targesome, Inc.	12-05-2002	
	B61	WO	03/035839	A2	DGI Biotechnologies, Inc.	05-01-2003	
	B62	WO	03/070747	A2	Novo Nordisk A/S	08-28-2003	
	B63	WO	03/084574	A1	Bracco International BV	10-16-2003	
	B64	WO	03/103581	A2	Genentech, Inc.	12-18-2003	
	B65	WO	2004/001064	A2	Dyax Corporation	12-31-2003	
	B66	WO	2004/058802	A1	Amersham Health AS	07-15-2004	
	B67	WO	2004/058803	A2	Amersham Health AS	07-15-2004	
	B68	WO	2004/064595	A2	Bracco International BV	08-05-2004	
	B69	WO	2004/065621	A1	Dyax Corp.	08-05-2004	
	B70	WO	2004/085617	A2	The Cleveland Clinic Foundation	10-07-2004	
	B71	WO	2004/108074	A2	Research Development Foundation	12-16-2004	
	B72	WO	2005/011722	A2	Ludwig Institute for Cancer Research	02-10-2005	
	B73	WO	2005/016963	A2	Ludwig Institute for Cancer Research	02-24-2005	
	B74	WO	2005/070472	A2	Sunnybrook and Women's College Health Sciences Centre	08-04-2005	
	B75	WO	2005/072417	A2	The Ohio State University Research Foundation	08-11-2005	
	B76	WO	2006/015385	A2	Sopherion Therapeutics, Inc.	02-09-2006	

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C18	BINETRUY-TOURNAIRE et al., Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J. 2000 Apr 3;19(7):1525-33.	
	C19	HARVATH et al., Laminin peptides stimulate human neutrophil motility. J Immunol. 1994 Jun 1;152(11):5447-56.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/661,156	ATTY. DOCKET NO.: D0617.70012US00
				FILING DATE: September 11, 2003	CONFIRMATION NO.: 6772
				APPLICANT: Sato et al.	
				GROUP ART UNIT: 1653	EXAMINER: Anand U. Desai
Sheet	4	of	4		

	C20	IWAMOTO et al., YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science. 1987 Nov 20;238(4830):1132-4.	
	C21	JIA et al., Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF. Biochem Biophys Res Commun. 2001 Apr 27;283(1):164-73.	
	C22	LECOUTER et al., Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature. 2001 Aug 30;412(6850):877-84.	
	C23	SATO et al., Development of mammalian serum albumin affinity purification media by peptide phage display. Biotechnol Prog. 2002 Mar-Apr;18(2):182-92.	
	C24	SHRIVASTAVA et al., A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases. Protein Eng Des Sel. 2005 Sep;18(9):417-24.	

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.